KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Operating Expenses data on record, last reported at $517.2 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 4.12% year-over-year to $517.2 million; the TTM value through Dec 2025 reached $721.5 million, down 57.15%, while the annual FY2025 figure was $583.6 million, 65.34% down from the prior year.
  • Operating Expenses reached $517.2 million in Q4 2025 per SRPT's latest filing, up from -$911.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $583.6 million in Q1 2025 and bottomed at -$911.4 million in Q3 2025.
  • Average Operating Expenses over 5 years is $327.4 million, with a median of $368.7 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 61.54% in 2022, then crashed 304.83% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $307.3 million in 2021, then increased by 18.87% to $365.3 million in 2022, then increased by 1.89% to $372.2 million in 2023, then soared by 33.47% to $496.7 million in 2024, then rose by 4.12% to $517.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $517.2 million in Q4 2025, -$911.4 million in Q3 2025, and $532.1 million in Q2 2025.